Vanguard Group
DYN icon

Vanguard Group’s Dyne Therapeutics DYN Stock Holding History

Vanguard Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$219M Buy
11,215,565
+1,455,151
+15% +$27.6M ﹤0.01% 1503
2025
Q3 		$123M Buy
9,760,414
+2,109,257
+28% +$24.1M ﹤0.01% 1759
2025
Q2 		$72.8M Buy
7,651,157
+244,813
+3% +$2.7M ﹤0.01% 1962
2025
Q1 		$77.5M Buy
7,406,344
+702,418
+10% +$10M ﹤0.01% 1901
2024
Q4 		$158M Sell
6,703,926
-160,211
-2% -$4.74M ﹤0.01% 1646
2024
Q3 		$247M Buy
6,864,137
+2,146,083
+45% +$85.4M ﹤0.01% 1433
2024
Q2 		$167M Buy
4,718,054
+1,277,784
+37% +$37.1M ﹤0.01% 1591
2024
Q1 		$97.7M Buy
3,440,270
+1,110,629
+48% +$25.1M ﹤0.01% 1885
2023
Q4 		$31M Sell
2,329,641
-34,673
-1% -$339K ﹤0.01% 2395
2023
Q3 		$21.2M Sell
2,364,314
-24,427
-1% -$263K ﹤0.01% 2527
2023
Q2 		$26.9M Buy
2,388,741
+941,984
+65% +$11.1M ﹤0.01% 2465
2023
Q1 		$16.7M Sell
1,446,757
-197,653
-12% -$2.57M ﹤0.01% 2670
2022
Q4 		$19.1M Buy
1,644,410
+306,045
+23% +$3.54M ﹤0.01% 2651
2022
Q3 		$17M Buy
1,338,365
+17,140
+1% +$197K ﹤0.01% 2704
2022
Q2 		$9.08M Sell
1,321,225
-72,716
-5% -$501K ﹤0.01% 3049
2022
Q1 		$13.4M Buy
1,393,941
+1,219
+0.1% +$10.4K ﹤0.01% 2993
2021
Q4 		$16.6M Buy
1,392,722
+99,380
+8% +$1.4M ﹤0.01% 2940
2021
Q3 		$21M Buy
1,293,342
+78,459
+6% +$1.39M ﹤0.01% 2839
2021
Q2 		$25.6M Buy
1,214,883
+340,910
+39% +$6.41M ﹤0.01% 2722
2021
Q1 		$13.6M Buy
873,973
+183,391
+27% +$3.55M ﹤0.01% 2994
2020
Q4 		$14.5M Buy
690,582
+645,582
+1,435% +$12.8M ﹤0.01% 2799
2020
Q3 		$908K Buy
+45,000
New +$988K ﹤0.01% 3679

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group's DYN Position: Q4 2025 in Review

Vanguard Group increased its Dyne Therapeutics (DYN) stake by 15% in Q4 2025, buying an estimated $27.6M and bringing the position to 11,215,565 shares worth $219M. The position accounts for ﹤0.01% of the portfolio, ranked #1503.

Vanguard Group first reported a position in DYN in Q3 2020 and has held it in 22 quarters since. The position peaked at $247M in Q3 2024. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

  • Vanguard Group held 11,215,565 shares of Dyne Therapeutics worth $219M as of Q4 2025.
  • Vanguard Group bought 1,455,151 Dyne Therapeutics shares in Q4 2025, an estimated $27.6M.
  • Dyne Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1503 holding.
  • Vanguard Group first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Vanguard Group's Dyne Therapeutics position peaked at $247M in Q3 2024.
  • 232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.